15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Larimar Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $5.00 to $21.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $12.71 sits 232% above the current $3.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.42 next quarter toward $-1.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Larimar Therapeutics Inc.
As of Jul, 7 of 7 firms rate LRMR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LRMR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.51 – $-0.35 · 8 analysts · -31% YoY
Next period, 8 analysts expect Larimar Therapeutics Inc to earn $-0.42 a share (range $-0.51 – $-0.35), versus $-0.61 a year earlier. Full-year consensus is $-1.61, growing to $-1.18 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $57.1M next year.
Top analysts covering Larimar Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LRMR.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$26.00+579.7% to target
Overall win rate
52%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$18.00+370.6% to target
Overall win rate
44%
+ Follow
#3
Joel Beatty
Baird · Rank #111
Buy
$5.00+30.7% to target
Overall win rate
46%
+ Follow
#4
Laura Chico
Wedbush · Rank #122
Buy
$12.00+213.7% to target
Overall win rate
40%
+ Follow
#5
EW
Edward White
HC Wainwright & Co. · Rank #241
Buy
$16.00+318.3% to target
Overall win rate
31%
+ Follow
LRMR stock forecast FAQ
What is LRMR's average 12-month price target?+
The 7 analysts with a live target average $12.71 for Larimar Therapeutics Inc over the next 12 months, ranging from a $21.00 high to a $5.00 low.
Is LRMR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LRMR?+
The Street-high target is $21.00 (Oppenheimer), and the Street-low is $5.00 (Baird). The average of all 7 active targets is $12.71.
How many Wall Street analysts cover LRMR?+
7 analysts have an active rating on Larimar Therapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering LRMR?+
Among analysts who currently cover LRMR, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $26.00 target.
What is Larimar Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.51 – $-0.35) across 8 analysts. Full-year EPS is projected at $-1.61, rising to $-1.18 the following year.
How much revenue is Larimar Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $57.1M next year.
Have analysts been upgrading or downgrading LRMR lately?+
As of Jul, 7 of 7 firms rate LRMR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LRMR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
